{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-006132","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.753536+00:00","generated_at":"2026-06-18T11:39:24.051440+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Corbus Pharmaceuticals appoints Yong Ben, M.D., MBA to Board of Directors","bullets":["Dr. Ben appointed to board effective March 1, 2023; press release issued March 6, 2023.","He brings over 20 years of oncology drug development experience, including roles at BeiGene, BioAtla, and AstraZeneca.","Initial option grant of 5,307 shares; annual cash retainer of $40,000 and annual stock option grant.","Company also entered into standard indemnification agreement with Dr. Ben.","Appointment supports Corbus' precision oncology pipeline including CRB-701 and CRB-601."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-006132","json":"https://secwatch.observer/filing/0000950170-23-006132.json","markdown":"https://secwatch.observer/filing/0000950170-23-006132.md","text":"https://secwatch.observer/filing/0000950170-23-006132.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000095017023006132/0000950170-23-006132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000095017023006132/crbp-20230301.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:39:24.051440+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"92332185dc","claim":"Yong Ben was appointed as member of the Board at Corbus Pharmaceuticals Holdings, Inc..","evidence_excerpt":"On March 1, 2023, the Board of Directors (the “Board”) of Corbus Pharmaceuticals Holdings, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Yong Ben, M.D., MBA, age 49, to serve as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1595097/000095017023006132/0000950170-23-006132-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"member of the Board"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}